-
Alan Bonder, MD: Phase 2 Data for Combination Obeticholic Acid, Bezafibrate in PBC
28 May 2024 21:46 GMT
… , associate professor of medicine at Harvard Medical School and medical director of liver … transplantation at Beth Israel Deaconess Medical Center.
HCPLive: Can you … relevant disclosures with Intercept, GSK, Ipsen, Miriam, and others.
Reference:
Bonder …
-
FDA denies Ipsen's citizen petition for blockbuster drug Somatuline
24 May 2024 18:01 GMT
US drug regulators have turned down Ipsen’s effort to … slow down generic competition for its blockbuster drug … generic versions of the drug approved. Somatuline was first … filings. Revenue from the drug has been declining as …
-
Acromegaly Pipeline Drugs Analysis Report (2024 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA By Delveinsight | Pfizer Inc, Novartis AG, Validus Pharma, Ipsen, Chiasma, Inc, Crinetics
20 May 2024 20:44 GMT
… Pharmaceuticals LLC, Ipsen, Chiasma, Inc, Crinetics Pharmaceuticals, Ionis Pharmaceuticals Inc, Midatech Pharma Plc, ADVANZ PHARMA, Amolyt Pharma … Pipeline Drug Insight
Coverage: Global Key Acromegaly Companies: OPKO Health, Amolyt Pharma, Debiopharm …
-
Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock
10 May 2024 20:48 GMT
… the Ipsen and Elevation Oncology agreements.
ABOUT MERRIMACK
Merrimack Pharmaceuticals, … Ipsen upon approval by the U.S. Food and Drug … manufacturing that could lead Ipsen and Elevation Oncology and … authorities may disagree with Ipsen and Elevation Oncology’s …
-
Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution
09 May 2024 11:51 GMT
… CONTAIN IMPORTANT INFORMATION ABOUT MERRIMACK PHARMACEUTICALS, INC., THE PROPOSED DISSOLUTION, THE … merrimack.com.
ABOUT MERRIMACK
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company … by Ipsen upon approval by the U.S. Food and Drug Administration …
-
Royalty Pharma Reports First Quarter 2024 Results
09 May 2024 11:00 GMT
… the ongoing wave of healthcare innovation. Based on … /Cometriq
Exelixis, Ipsen, Takeda
Cancer
18
16 … Food & Drug Administration and the European Medicines Agency, respectively, … to leading global pharmaceutical companies. Royalty Pharma has assembled a …
-
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2024 Earnings Call Transcript
08 May 2024 15:36 GMT
… Transcript May 7, 2024
Rhythm Pharmaceuticals, Inc. misses on earnings … with hypothalamic obesity on commercial drug through the pre-EMEA … the 5% royalty to Ipsen under our original licensing … again, the Medicaid population, in addition to the health of the …
-
Congruence Therapeutics Appoints Experienced Drug Developer Michael D. Harvey, Ph.D. as Chief Development Officer
07 May 2024 08:54 GMT
… for diseases with significant unmet medical need, announced today the appointment … , Drug Development for rare diseases at Ipsen, following the acquisition of Clementia Pharmaceuticals … Inc., which led to US FDA and Health Canada …
-
Parkinson's Disease Levodopa-Induced Dyskinesia Market was ~USD 1,500 Million in 2023, estimated DelveInsight
27 May 2024 13:00 GMT
… , Bukwang Pharmaceutical/;Contera Pharma, Vistagen, Ipsen Pharma, Newron Pharmaceuticals/;Zambon Pharmaceuticals, and Celon Pharma SA, and … Induced Dyskinesia Drugs in development @ Parkinson' … leading healthcare-focused market research and consulting …
-
Ipsen Appoints EVP, President of North America
03 May 2024 21:06 GMT
… Yale under a Howard Hughes Medical Fellowship.
“I’m excited to … partnering with Ipsen’s employees, customers, and stakeholders across the healthcare ecosystem … , get special offers
from American Pharmaceutical Review – all delivered right to …